Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Unstable Angina Pectoris · Gastric Carcinoma · COLL

COLLEGIUM PHARMACEUTICAL

COLLEGIUM PHARMACEUTICAL, INC

COLLEGIUM PHARMACEUTICAL clinical programs — 29 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
100 Technology Center Dr, Stoughton, Massachusetts 02072, US HQ
617 Employees
Public company Type
COLL · NYSE Ticker
Company details
Status
Public
HQ
100 Technology Center Dr, Stoughton, Massachusetts 02072, US
Employees
617
Programs
29
Drugs
48
Patents
28
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

COLLEGIUM PHARMACEUTICAL projects

29 ClinicalTrials.gov programs sponsored by COLLEGIUM PHARMACEUTICAL.

COLLEGIUM PHARMACEUTICAL has 29 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

29 programs

Clinical programs

  1. AERD-COV19

    COLLEGIUM PHARMACEUTICAL, INC

    aspirin-exacerbated respiratory disease

    phase 3 small molecule active

    1 trial

  2. CADET-PAD

    COLLEGIUM PHARMACEUTICAL, INC

    Ischemia of the lower limbs in the course of obstructive artery disease

    phase 3 small molecule active

    1 trial

  3. DICES

    COLLEGIUM PHARMACEUTICAL, INC

    Breast cancer

    phase 3 other active

    1 trial

  4. De-escalation to ticagrelor 60 mg at day 30

    COLLEGIUM PHARMACEUTICAL, INC

    Non ST Segment Elevation Acute Coronary Syndrome

    phase 3 small molecule active

    1 trial

  5. Empagliflozin 10 MG

    COLLEGIUM PHARMACEUTICAL, INC

    Acute Decompensated Heart Failure

    phase 3 small molecule active

    1 trial

  6. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial

  7. Evolocumab

    COLLEGIUM PHARMACEUTICAL, INC

    Sars-CoV-2 Infection

    phase 3 small molecule completed

    1 trial

  8. HLD200 methylphenidate hydrochloride capsules

    COLLEGIUM PHARMACEUTICAL, INC

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  9. HYP-NOR

    COLLEGIUM PHARMACEUTICAL, INC

    hypotension in non-cardiac surgery

    phase 3 small molecule active

    1 trial

  10. IRINOTECAN

    COLLEGIUM PHARMACEUTICAL, INC

    Gastric Carcinoma

    phase 3 small molecule active

    1 trial

  11. Methoxyflurane - Penthrox

    COLLEGIUM PHARMACEUTICAL, INC

    ST Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  12. Oxycodone DETERx

    COLLEGIUM PHARMACEUTICAL, INC

    Chronic Low Back Pain

    phase 3 small molecule completed

    1 trial

  13. PB_A&A-ASC-FISTULA_1

    COLLEGIUM PHARMACEUTICAL, INC

    Anal or recto-cutaneous or recto-vaginal Crohn-related fistula

    phase 3 other active

    1 trial

  14. PREVENT-MINS

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Injury after Noncardiac Surgery

    phase 3 small molecule active

    1 trial

  15. Qarziba 4.5 mg/mL concentrate for solution for infusion

    COLLEGIUM PHARMACEUTICAL, INC

    Recurrent or progression of neuroblastoma or neuroblastoma or neuroblastoma refractory to first-line treatment.

    phase 3 small molecule active

    1 trial

  16. Ticagrelor 90 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  17. Ticagrelor 90mg

    COLLEGIUM PHARMACEUTICAL, INC

    STEMI

    phase 3 small molecule active

    1 trial

  18. Crushed ticagrelor followed by morphine

    COLLEGIUM PHARMACEUTICAL, INC

    Unstable Angina Pectoris

    approved small molecule completed

    2 trials

  19. Levosimendan

    COLLEGIUM PHARMACEUTICAL, INC

    Systolic Heart Failure

    approved small molecule active

    1 trial

  20. Morphine

    COLLEGIUM PHARMACEUTICAL, INC

    ST-segment Elevation Myocardial Infarction

    approved small molecule completed

    1 trial

  21. Pulverized ticagrelor sublingually

    COLLEGIUM PHARMACEUTICAL, INC

    Unstable Angina Pectoris

    approved small molecule completed

    1 trial

  22. Rifaximin

    COLLEGIUM PHARMACEUTICAL, INC

    ACS - Acute Coronary Syndrome

    approved small molecule active

    1 trial

  23. Rosuvastatin and Ezetimibe morning or evening administration

    COLLEGIUM PHARMACEUTICAL, INC

    Hypercholesterolemia

    approved small molecule completed

    1 trial

  24. Ticagrelor followed with Methoxyflurane

    COLLEGIUM PHARMACEUTICAL, INC

    Unstable Angina

    approved small molecule completed

    1 trial

  25. Xtampza ER (oxycodone)

    COLLEGIUM PHARMACEUTICAL, INC

    Chronic Pain

    approved small molecule terminated

    1 trial

  26. Gold omega 3

    COLLEGIUM PHARMACEUTICAL, INC

    Chronic Kidney Disease

    other active

    1 trial

  27. Immunological Factors

    COLLEGIUM PHARMACEUTICAL, INC

    Neuropathic Pain

    other active

    1 trial

  28. Oral Chondroitin Sulfate (Flextrum)

    COLLEGIUM PHARMACEUTICAL, INC

    Meniscus Lesion

    other completed

    1 trial

  29. Platelet-rich plasma

    COLLEGIUM PHARMACEUTICAL, INC

    ACL Injury

    mab active

    1 trial

Frequently asked questions

How many clinical projects does COLLEGIUM PHARMACEUTICAL have?

29 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.